COVID-19 and tuberculosis-threats and opportunities.

Immunotherapy Programme, Champalimaud Centre for the Unknown, Lisbon, Portugal; I Med Clinic, University of Mainz, Mainz, Germany; Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Zambia National Public Health Institute, Ministry of Health, Lusaka, Zambia; Foundation Congolaise pour la Recherche Médicale/University Marien Ngouabi Brazzaville, Congo; Institute for Tropical Medicine/University of Tübingen, Germany; Ministry of Health, Lusaka, Zambia; National Institute of Medical Research, Dar es Salaam, Tanzania; Servizio di Epidemiologia Clinica

[1]  T. Lam,et al.  Mask wearing to complement social distancing and save lives during COVID-19. , 2020, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[2]  A. Spanevello,et al.  Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases , 2020, European Respiratory Journal.

[3]  C. Cordon-Cardo,et al.  Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy — Achieving global consensus and visibility for cellular host-directed therapies , 2020, International Journal of Infectious Diseases.

[4]  A. Spanevello,et al.  Tuberculosis, COVID-19 and migrants: Preliminary analysis of deaths occurring in 69 patients from two cohorts , 2020, Pulmonology.

[5]  D. Cirillo,et al.  The prospects for the SARS‐CoV‐2 pandemic in Africa , 2020, EMBO Molecular Medicine.

[6]  Tai Hing Lam,et al.  Wearing face masks in the community during the COVID-19 pandemic: altruism and solidarity , 2020, The Lancet.

[7]  M. Niederman,et al.  The explosive epidemic outbreak of novel coronavirus disease 2019 (COVID-19) and the persistent threat of respiratory tract infectious diseases to global health security , 2020, Current opinion in pulmonary medicine.

[8]  Tai Hing Lam,et al.  Mass masking in the COVID-19 epidemic: people need guidance , 2020, The Lancet.

[9]  G. Ippolito,et al.  Host-directed therapies and holistic care for tuberculosis. , 2020, The Lancet. Respiratory medicine.

[10]  Alimuddin Zumla,et al.  Post TB treatment infectious complications. , 2020, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[11]  D. Hui,et al.  Emerging and Reemerging Infectious Diseases: Global Overview , 2019, Infectious Disease Clinics of North America.

[12]  T. Sorrell,et al.  Advancing Planetary Health in Australia: focus on emerging infections and antimicrobial resistance , 2019, BMJ Global Health.

[13]  S. Hoffman,et al.  Delays in Global Disease Outbreak Responses: Lessons from H1N1, Ebola, and Zika , 2018, American journal of public health.

[14]  S. Galwankar,et al.  The Forgotten Plague: Psychiatric Manifestations of Ebola, Zika, and Emerging Infectious Diseases , 2017, Journal of global infectious diseases.

[15]  P. Kaleebu,et al.  Taking forward a ‘One Health’ approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential , 2016, International Journal of Infectious Diseases.

[16]  Alimuddin Zumla,et al.  Emerging infectious diseases and pandemic potential: status quo and reducing risk of global spread , 2014, The Lancet Infectious Diseases.

[17]  Z. Memish,et al.  Severe acute respiratory syndrome vs. the Middle East respiratory syndrome , 2014, Current opinion in pulmonary medicine.

[18]  A. Skrahin,et al.  Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with multidrug and extensively drug-resistant tuberculosis: an open-label phase 1 safety trial. , 2014, The Lancet. Respiratory medicine.

[19]  S. Nava,et al.  Early consensus management for non-ICU ARF SARS-CoV-2 emergency in Italy: from ward to trenches , 2020 .